US FDA’s Cavazzoni To Manufacturers: Pay Attention To Data Received From CROs

 
• By Anju Ghangurde

Manufacturers should keep a sharp eye on data from contract research organizations, looking for “any irregularities” amid a concerning trend of data integrity issues pertaining to BA/BE studies conducted by certain CROs in India, the director of the FDA’s drug center says.

The FDA flags concerns about data integrity issues at CROs • Source: Shutterstock

More from Regulation

More from Policy & Regulation